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Abstract
Background and purpose: Metabolic disturbances of excita-
tory and inhibitory neurotransmitters are implicated in patho-
genesis of Tourette syndrome (TS). The aim of the study was
to measure serum concentrations of glutamic acid, 
γ-aminobutyric acid (GABA) and glycine in TS patients and
evaluate any correlation between neurotransmitter levels and
age at onset, actual age, gender, tic severity, duration of the
disease and concomitant psychiatric disorders.
Material and methods: Sixty-seven TS patients, aged 16-59,
and 57 healthy controls, aged 19-37, were enrolled in the
study. Information regarding medical history and physical
investigation was collected using a short questionnaire. Six-
ty-seven percent of patients were medication-free at the time
of examination and the rest had withheld treatment for 
24 hours before. Blood samples were taken after a 12-hour
fasting period. HPLC technique was used.
Results: The TS group had higher glutamic acid and lower
GABA levels. Glycine concentrations were comparable. No
differences regarding neurotransmitter concentrations
between treated and non-treated patients were found. Patients
with concomitant obsessive-compulsive disorder and severe
tics had higher glutamate levels. Glutamate concentrations
correlated positively with the number of comorbid psychi-
atric disorders and GABA concentrations correlated nega-
tively with the number of behavioural problems in patients
with comorbidities. There was no correlation between
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St reszczenie
Wstêp i cel pracy: Zaburzenia metabolizmu neuroprzekaŸ -
ników pobudzaj¹cych i hamuj¹cych odgrywaj¹ rolê w pato-
genezie zespo³u Tourette’a. Celem pracy by³a analiza stê¿enia
kwasu glutaminowego, γ-aminomas³owego (GABA) i glicy-
ny w surowicy chorych z zespo³em Tourette’a oraz ocena
zale¿noœci pomiêdzy stê¿eniami neurotransmiterów a wie-
kiem lub p³ci¹, wiekiem w chwili zachorowania, nasileniem
tików, czasem trwania choroby i wspó³istniej¹cymi zaburze-
niami psychiatrycznymi.
Materia³ i metody: Zbadano 67 chorych na zespó³ Tourette’a
w wieku 16–59 lat oraz 57 zdrowych osób w wieku 19–37 lat.
Wykorzystano ankietê obejmuj¹c¹ informacje z badania pod-
miotowego i przedmiotowego. Szeœædziesi¹t siedem procent
chorych nie przyjmowa³o ¿adnych leków w momencie bada-
nia, u pozosta³ych wstrzymano podawanie 24 godziny przed
pobraniem krwi. Próbki zebrano po 12-godzinnym okresie
na czczo. Oznaczeñ dokonano metod¹ HPLC.
Wyniki: W grupie chorych stê¿enie kwasu glutaminowego
by³o wiêksze, zaœ GABA – mniejsze. Stê¿enie glicyny by³o
podobne. Nie stwierdzono istotnej ró¿nicy stê¿eñ neuro-
przekaŸników pomiêdzy grup¹ osób leczonych i nieleczonych.
W grupie osób ze wspó³istniej¹cym zaburzeniem obsesyjno-
-kompulsywnym oraz ciê¿kim nasileniem tików stê¿enie kwa-
su glutaminowego by³o wiêksze. Stwierdzono dodatni¹ kore-
lacjê pomiêdzy stê¿eniem kwasu glutaminowego a liczb¹
dodatkowych zaburzeñ psychiatrycznych oraz odwrotn¹ kore-
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Introduction
Tourette syndrome (TS) consists of multiple motor
tics and at least one vocal tic that are present for more
than 12 months. Diagnostic criteria are given in the
DSM-IV-TR classification [1]. TS affects both chil-
dren and young adults and is frequently associated with
other psychiatric disorders. The most common are atten-
tion deficit hyperactivity disorder (ADHD), obsessive-
compulsive disorder (OCD), mood and conduct dis-
order, anger control problems and self-injurious
behaviour [2].
The aetiology of TS remains unknown. It is pro-
posed though that genetic and autoimmune factors play
a significant role in the pathogenesis of the condition
[3]. Excessive dopaminergic transmission seems to be
of great importance in the pathophysiology of tics, but
other neurotransmitter system disturbances (noradren-
ergic, cholinergic, GABA-ergic, glutaminergic, sero-
toninergic, opioid) are also present [4]. This disorder
results from improper function of neurotransmitter
transmission in cortico-subcortical loops composed of
cortex, striatum, globus pallidus and thalamus. GABA
and glutamic acid transmit the information and
dopamine modulates their function [5]. Thus, the
symptoms in TS are provoked by an imbalance in the
excitatory and inhibitory system in the cortico-striato-
thalamo-cortical loop [4].
The aim of our study was to assess whether changes
in neurotransmitter concentrations in TS patients’ brains
may be reflected by their levels in serum and whether
serum levels of selected amino acids can be a marker of
the severity or clinical phenotype of the disease.
We chose glutamic acid and GABA as they are the
main transmitting chemicals in the basal ganglia, and
glycine, which plays a role similar to GABA, but main-
ly in the spinal cord. 
Material and methods
Sixty-seven TS patients (55 males and 12 females)
of mean age 24.8 ±7.9 years (range: 16-59) were includ-
ed in the study, as well as 57 healthy controls (29 males
and 28 females) of mean age 25.7 ±3.7 years (range:
19-37). No person under the age of 16 was included in
the study. In 34.3% (23/67) of patients with TS, allergy
to different agents was found in their medical history,
but no acute allergic reaction was present and no anti-
allergics were used in any TS patient at the time of exa-
mination. Each of the following: bronchial asthma,
Hashimoto disease and essential tremor were found 
in one patient only. The remaining 61.2% (41/67) of
patients with TS had negative medical history. Physical
examination was performed in every patient and revealed
no findings except tics and other TS symptoms. The
average age at tic onset in the TS group was 8.2 ± 3.6
years (range: 3-17).
A short questionnaire was used to obtain basic demo-
graphic data (age, gender), details about TS (age of tic
onset, its severity, family history and treatment), con-
comitant psychiatric disorders and behavioural problems. 
The diagnosis of TS and other comorbid psychiatric
disorders was made using DSM-IV-TR criteria [1].
The TS patient group was further divided in two sub-
groups: TS-plus (49/67, 73.1%), with comorbidities
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analysed neurochemicals and age, gender, age at onset or dis-
ease duration.
Conclusions: Imbalance between excitatory and inhibitory
systems in the brains of TS patients may be reflected by glu-
tamate and GABA serum level changes. Glutamate and
GABA may be biomarkers of the disease and high concen-
tration of glutamate may indicate more severe course of TS.
Key words: Tourette syndrome, amino acids, neurotransmit-
ters, glutamate, γ-aminobutyric acid, glycine. 
lacjê pomiêdzy stê¿eniem GABA a liczb¹ zaburzeñ behawio-
ralnych w grupie ze wspó³istniej¹cymi zaburzeniami psychia-
trycznymi. Nie stwierdzono korelacji pomiêdzy stê¿eniami ana-
lizowanych neuroprzekaŸników a wiekiem lub p³ci¹ pacjentów,
wiekiem zachorowania ani czasem trwania choroby. 
Wnioski: Zaburzenie równowagi pomiêdzy uk³adem pobu-
dzaj¹cym i hamuj¹cym w mózgu chorych z zespo³em Touret-
te’a mo¿e siê manifestowaæ zmianami stê¿eñ kwasu glutami-
nowego i GABA w surowicy. Kwas glutaminowy i GABA
mog¹ byæ markerami choroby, a du¿e stê¿enie glutaminianu
we krwi chorych mo¿e oznaczaæ ciê¿szy przebieg zespo³u
Tourette’a.
S³owa kluczowe: zespó³ Tourette’a, aminokwasy, neuro -
przekaŸniki, kwas glutaminowy, kwas γ-aminomas³owy, 
glicyna.
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parallel to tics, and TS-only (18/67, 26.9%), without
psychiatric disorders. The TS-plus group included
patients with attention deficit hyperactivity disorder
(ADHD, 24/67, 35.8%), obsessive-compulsive disor-
der (OCD, 23/67, 34.3%), learning disorder (23/67,
34.3%), anxiety disorder (15/67, 22.4%), conduct dis-
order (6/67, 9.0%), mood disorder (11/67, 16.4%),
enuresis not related to a general medical condition (5/67,
7.5%), stuttering (7/67, 10.4%) and trichotillomania
(3/67, 4.5%). 
Behavioural problems that have no strict definition in
DSM-IV-TR were diagnosed on the basis of clinical expe-
rience of the investigator and included: sleep and anger
control problems, sexually inappropriate behaviours, self-
injurious behaviour and problems with social skills. 
Tic intensity was described as peak tic severity any
time in the course of the disease. Mild tics did not sig-
nificantly impair normal daily living and never
required treatment with neuroleptics. Severe tics sig-
nificantly interfered with normal daily activities and
prevented patients from leading a normal life despite
treatment. The majority of individuals (81%; 54/67)
had mild tics, and the other 19% of patients (13/67)
had severe tics.
At the time of blood sample collection a minority of
the patients were taking medicines (33%, 22/67), main-
ly for tics. The most common kind of medicines used
were neuroleptics such as haloperidol (7 cases, range of
daily dose: 2-5 mg per day), risperidone (3 cases, range:
1-4 mg), tiapride (3 cases; range: 200-600 mg) and
olanzapine (2 cases, range: 5-10 mg). Popular non-neu-
roleptics were: clonidine (4 cases, range: 150-225 μg)
and antidepressive agents: sertraline (2 cases, 50 mg),
clomipramine (1 case, 75 mg), fluoxetine (1 case,
40 mg) and citalopram (1 case, 20 mg). At the time of
blood sample collection, all of the participants were drug
free for at least 24 hours.
Blood samples were collected after a 12-hour period
of fasting. Only still water was allowed. Serum amino
acids were analysed according to a modified isocratic
Pico Tag method by high performance liquid chro-
matography (HPLC) on the Shimadzu HPLC system
equipped with the Waters reverse phase column
(Spherisorb ODS2 3 μm and 4.6 × 250 mm) [6]. UV
detection was performed at 254 nm and standards of
amino acids used for quantitation were purchased from
Sigma. 
The study was approved by the institutional ethical
review board and all patients and controls signed
informed consent. In the case of a patient below the age
of 18, the informed consent was obtained both from one
of the parents and the child. 
Statistical analysis
All statistical analyses were performed by means of the
program Statistica v. 8.0. Quantitative data are shown as
median (minimum, maximum) and the Mann-Whitney
U-test was used to compare the results. Qualitative data
were analysed using the χ2 test. Spearman’s rank corre-
lation coefficient was used to evaluate the correlation. 
A p-value of less than 0.05 was considered as significant.
Results
The TS group had statistically higher concentration
of glutamate than controls (p < 0.001) and lower con-
centration of GABA than controls (p < 0.05). No sig-
nificant difference between the groups was found
regarding glycine concentration ( p = 0.37) (Fig. 1). No
relationship between amino acid serum concentrations
and patients’ age, age at tic onset or disease duration
was found. No differences were found between males
and females regarding concentrations of examined
amino acids in the TS group and controls (Table 1). Posi-
tive family history (52.2%, 35/67) did not influence
amino acid concentrations compared to TS patients with
negative family history (data not shown).
The amino acid concentrations did not show any sta-
tistical differences in the TS-only compared to the 
TS-plus group (Table 2). We compared groups of TS
patients with regard to the presence or absence of each
comorbid psychiatric disorder. Only individuals with
OCD had higher concentrations of glutamate (median
1.21 μg/L [0.12; 4.79] vs. 0.48 μg/L [0.05; 5.87],
respectively; p < 0.05) and those with learning disor-
ders had lower concentrations of GABA (median
0.11 μg/L [0.00; 0.40] vs. 0.15 μg/L [0.00; 0.38],
respectively; p < 0.05). Patients with ADHD, anxiety
disorder, conduct disorder, mood disorder, enuresis,
stuttering and trichotillomania had similar concentra-
tions of amino acids compared to the group of patients
not having the particular disorder.
Spearman correlation analysis showed that in the
comorbid TS patients (TS-plus group) the concentra-
tion of glutamate increased along with the number of
other psychiatric disorders (Fig. 2A), while the con-
centration of GABA decreased along with the number
of behavioural problems per patient (Fig. 2B). The
number of behavioural problems correlated positively
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with the number of psychiatric disorders in the TS-plus
group (Spearman r = 0.60; p < 0.05). 
Glutamate appeared to be the only amino acid that
had an association with severe tics compared to mild tics
in the course of the disease (Fig. 3).
The comparison of patients pharmacologically treat-
ed and not treated at the time of examination revealed
no statistically significant differences in relation to amino
acid concentrations (Table 3).
Discussion
The main findings of our study are that the concen-
tration of glutamate is higher and GABA is lower in TS
patients’ serum compared to controls. It remains unclear
whether serum glutamate and GABA levels truly reflect
their brain activity as we did not measure brain or cere-
brospinal fluid levels of these amino acids. However, we
speculate that the changes in serum glutamate and
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Fig. 1. Neurotransmitter serum concentrations in Tourette syndrome patients and control group. Values are shown as medians (minimum; maximum)
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*p < 0.001; **p < 0.05; GABA – γ-aminobutyric acid
Patients with Tourette syndrome Controls 
Males Females p-value Males Females p-value
n = 55 n = 12 n = 29 n = 28
Glutamate 0.65 0.85 0.701 0.35 0.24 0.768 
(μg/L) (0.06; 5.87) (0.05; 2.9) (0.0; 2.1) (0.10; 1.84)
GABA 0.14 0.13 0.948 0.21 0.16 0.122
(μg/L) (0.0; 0.4) (0.08; 0.27) (0.0; 0.5) (0.02; 0.30)
Glycine 7.29 6.28 0.452 7.84 5.00 0.091
(μg/L) (0.0; 15.98) (1.85; 12.9) (0.71; 13.7) (1.03; 10.50)
Table 1. Neurotransmitter concentrations in males and females in TS and control groups. Values are shown as medians (minimum; maximum)
GABA – γ-aminobutyric acid
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GABA may reflect the changes in the brain. There are
many papers in the literature on amino acid and neuro-
transmitter concentrations in serum of individuals with
psychiatric disorders. High concentrations of serum glu-
tamate have been associated with schizophrenia, autism,
and alcohol withdrawal [7-9]. Low concentrations of
serum GABA have been found in depression, post-
traumatic stress disorder, and alcohol addiction [10].
The authors of these papers concluded that findings in
serum amino acid concentrations were important in
understanding the pathogenesis of these disorders
because they may be related to brain levels. 
The organization of the blood-brain barrier promotes
the net removal of most amino acids including gluta-
mate against a concentration gradient from brain to
blood. Glutamate transporters (EAAT1, 2 and 3) are
able to pump it from the brain into endothelial cells that
form the blood-brain barrier and facilitative carrier xG-
for glutamate at the luminal (blood-facing) membrane
provides a mechanism for removing it from brain to
blood [11]. The lack of facilitative glutamate transport
carriers on the abluminal (brain-facing) membrane pre-
vents movement of glutamate into the brain [12]. When
intracellular glutamate becomes greater than the plas-
ma concentration, net transport of glutamate across the
luminal membrane into the blood will occur. A similar
mechanism exists for glutamine, which is converted to
glutamate by glutaminase in endothelial cells [11].
Additionally, our results regarding glutamate in serum
seem consistent with our previous findings in magnet-
ic resonance spectroscopy of TS patients’ brains, show-
ing higher glutamate concentrations in the thalamus and
lenticular nucleus [13]. Considering sources of gluta-
mate other than the brain, every patient underwent
a thorough physical examination and in every case it was
normal except for tics. No liver, kidney or alimentary
tract signs were found. With regard to allergy, no patient
with acute signs of allergic reaction was enrolled in the
study. 
The origin of plasma GABA in humans is difficult
to demonstrate directly, but indirect evidence suggests
that plasma GABA is largely derived from the brain.
GABA is a very CNS-specific compound, with 99% of
total body GABA and 95% of its synthesizing enzyme
glutamate decarboxylase being located in the brain and
the spinal cord [14]. GABA is transferred from the
brain interstitial fluid to the circulating blood across the
blood-brain barrier, which acts as an efflux pump for
GABA to reduce the brain concentration [15]. Trans-
port of GABA from the circulating blood to the brain
is very small [16,17]. A high correlation between plas-
TS-only TS-plus p-value
n = 18 n = 49
Glutamate 0.54 0.90 0.611
(μg/L) (0.06; 3.64) (0.05; 5.87)
GABA 0.15 0.13 0.362
(μg/L) (0.05; 0.31) (0.0; 0.40)
Glycine 6.91 7.21 0.893
(μg/L) (1.60; 12.8) (0.0; 15.98)
Table 2. Neurotransmitter concentrations in TS-only and TS-plus groups. 
Values are shown as medians (minimum; maximum)
TS – Tourette syndrome, GABA – γ-aminobutyric acid
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ma and CSF levels of GABA has been reported in rats
[18], dogs [19] and normal humans [20]. Changes in
plasma GABA appear to reflect changes in brain GABA
[21] and cerebrospinal fluid GABA [22,23]. Thus,
these data suggest that plasma GABA concentration is
likely to reflect brain GABA-ergic activity. 
To minimize the influence of food on amino acid
concentrations, the individuals enrolled in the study
were asked not to eat for 12 hours. We were aware that
ceasing treatment 24 hours before collecting blood was
not enough to eliminate its influence on amino acid lev-
els in serum. Hence, to exclude the influence of phar-
macological treatment on the findings we compared
the treated and untreated group of TS patients and did
not find any statistical difference (Table 3). Taking
everything into account, we believe that serum gluta-
mate and GABA derived from brain may reflect their
brain levels and should be considered in pathophysio -
logy of TS. 
The dopaminergic transmission in TS is increased
in basal ganglia [24,25]. Glutamic acid and GABA play
a significant role in excitation and inhibition of the basal
ganglia, yet dopamine is the main modulating chemical
of this system. Dopamine-containing neurons of the sub-
stantia nigra pars compacta (SNc) modulate the activi-
ty of GABA-ergic striatal neurons. They exert their
action by way of D1 receptors (direct pathway, an
increase of activity) and D2 receptors (indirect pathway,
a decrease of activity) [5]. Blocking the neuronal trans-
mission of the indirect pathway and/or increasing it in
the direct pathway underlie the pathophysiology of invol-
untary movements such as tics or chorea. Mutual influ-
ence exists: the modulating function of dopamine on the
GABA-ergic striatal neuronal projections’ activity is
exerted indirectly through GABA-ergic and choliner-
gic interneurons of the striatum [26]. In response,
GABA released from neurons of the striatal striosome
neurons inhibits dopaminergic neurons of the SNc. Low
concentration of GABA could explain the excessive
activity of dopamine-releasing neurons in SNc and thus
would indicate the increased activity of the dopaminer-
gic system in TS. However, there are only three papers
in the literature dealing with GABA content in the CNS
of TS patients. Two different studies conducted on the
same four brains of TS patients showed normal gluta-
mate decarboxylase activity [27] and GABA levels [28]
when compared to the brains of control subjects. In the
third one, cerebrospinal fluid GABA concentrations as
well as serum GABA levels of 15 patients with TS were
not significantly different from those of controls [29].
We do not confirm these findings as our study showed
lower content of serum GABA in TS patients. 
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Fig. 3. Medians (minimum; maximum) of neurotransmitter concentrations according to tic severity
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The dopaminergic system is closely connected with
the glutaminergic system. Acting through D1 receptors
dopamine enhances NMDA receptor-mediated respons-
es and through D2 receptors inhibits non-NMDA
receptor activity [30,31]. D1 receptor-mediated activ-
ity depends on the neuronal polarization state. In the
case of a depolarized neuron, it enhances this state and
at the same time causes insensitivity to any stimuli of the
neuron in the non-active (hyperpolarized) state [32,33].
The excessive concentration of glutamate in TS may
cause depolarization and this state could intensify the
action of dopamine. Due to the existence of D1-NMDA
heterodimer, the effect of up-regulation of the D1 recep-
tors caused by glutamate acting through NMDA is
greater [34]. This mechanism could explain the greater
dopamine activity in the case of higher glutamate con-
centrations in TS. There are some data on glutamate
levels in the brains of patients with TS. Autopsy of four
brains of patients with TS revealed lower glutamate con-
centration in the internal globus pallidus (GPi) by 30%
and to a smaller degree in the external globus pallidus
(GPe) and substantia nigra pars reticulata (SNr)
[28,35]. Because the GP and SNr receive their gluta-
matergic input from the subthalamic nucleus (STN), it
suggests that STN output may be reduced in TS.
Decreased excitatory input to the GPi would be expect-
ed to decrease activity in the inhibitory projection from
the GPi to the thalamus, leading to increased activity of
the thalamus and thalamo-cortical pathway. This hypoth-
esis is consistent with our previous findings of higher
concentration of glutamic acid in the thalami of 15 TS
patients compared to normal humans in magnetic reso-
nance spectroscopy of the brain [13]. It is possible that
glutamate levels are different in various regions of the
brains of TS patients and the net content of this amino
acid is elevated. This may be reflected by high gluta-
mate level in serum, as our present study has shown.
However, to date no studies have been published on the
concentration of glutamate in the cerebrospinal fluid and
serum of TS patients to confirm this hypothesis. 
There is no reliable marker of the disease that could
indicate the prognosis or the course of TS. Our results
may help to elaborate it. Glutamate level turned out to
be higher in patients with severe tics and a larger num-
ber of concomitant psychiatric disorders, especially with
obsessive-compulsive disorder. High concentration of
glutamic acid may be a useful marker of the disease
severity (its clinical phenotype and tic intensity), espe-
cially because it does not depend on the disease dura-
tion.
Children younger than 16 years of age were not stud-
ied, which might have influenced our results. It is known
though that TS symptoms in children are more pro-
nounced. Severity of tics and some of the concomitant
psychiatric disorders (e.g. ADHD) usually decreases
gradually after puberty [36]. In our study we did not
find any correlation between glutamate or GABA and
disease duration. This suggests that our findings should
not be significantly different from those obtained in chil-
dren. For ethical reasons we could not perform the lum-
bar puncture in patients with the diagnosis already stat-
ed and without any medical reasons. Due to the lack of
information on the correlation between cerebrospinal
fluid and serum concentrations of the neurotransmitters
we cannot prove beyond doubt cerebral origin of the
examined amino acids in serum. However, data from
the literature mentioned above make it highly probable. 
Our present results and previous findings of higher
glutamate levels in the basal ganglia in TS patients [13]
may suggest that in this condition the important pro-
voking factor is the imbalance between the glutaminer-
gic (excitatory) and GABA-ergic (inhibitory) systems.
Normal values of glycine concentrations in TS patients,
that is an inhibitory neurotransmitter in the spinal cord,
support the notion that the problem does not lie in spinal
cord function.
We conclude that the findings of this study may be
important for understanding the pathogenesis of TS and
predicting the course of the disease, though it should be
considered with great caution. 
Conclusions
1. Imbalance between excitatory and inhibitory systems
in the brain of TS patients is reflected by concentra-
tions of glutamate and GABA in serum.
Treated Untreated p-value
n = 55 n = 12
Glutamate 0.54 0.99 0.42
(μg/L) (0.05; 5.87) (0.10; 3.06)
GABA 0.14 0.13 0.67
(μg/L) (0.0; 0.40) (0.0; 0.27)
Glycine 7.20 7.01 0.83
(μg/L) (0.0; 15.98) (0.0; 12.90)
Table 3. Neurotransmitter concentrations in treated and untreated TS patients.
Values are shown as medians (minimum; maximum)
TS – Tourette syndrome, GABA – γ-aminobutyric acid
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2. Concentrations of glutamate and GABA may repre-
sent markers of the disease, and high concentration
of glutamate may predict more severe course of
Tourette syndrome.
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